| Virological failure | Low NNRTI concentrations | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
 | n/N | Univariate analysis | Multivariate analysis†| n/N | Univariate analysis | Multivariate analysis†| ||||
 |  | OR (95% CI) | P value | OR (95% CI) | P value |  | OR (95% CI) | P value | OR (95% CI) | P value |
M24 cohort (vs. M12) | 50/506 | 1.8 (1.1–3.0) | 0.02 | 2.0 (1.2–3.6) | 0.01 | 32/505 | 0.6 (0.4–1.0) | 0.06 | 0.7 (0.4–1.1) | 0.15 |
Age at ART start (vs. 15–34) |  |  |  |  |  |  |  |  |  |  |
   ≥ 35 years | 40/506 | 0.5 (0.3–0.9) | 0.02 | 0.5 (0.3–0.8) | 0.01 | 46/505 | 1.1 (0.7–1.9) | 0.58 | - | - |
School level (vs. secondary or higher) | ||||||||||
   Primary or no education | 47/506 | 0.8 (0.5–1.4) | 0.50 | - | - | 53/505 | 1.5 (0.9–2.6) | 0.14 | 1.3 (0.8–2.4) | 0.3 |
Non-cumulative WHO stage at survey (vs. asymptomatic) | ||||||||||
   Stage 1–2 | 32/490 | 1.9 (1.2–3.3) | 0.04 | 1.9 (1.1–3.3) | 0.06 |  |  |  |  |  |
   Stage 3–4 | 6/490 | 1.1 (0.4–2.8) |  | 0.8 (0.3–2.2) |  | - | - | - | - | - |
TB episode after ART | 11/506 | 2.1 (0.9–4.3) | 0.06 | 2.3 (1.0–5.0) | 0.04 | - | - | - | - | - |
Weight ≤ baseline | 32/506 | 1.9 (1.2–3.3) | 0.009 | 2.2 (1.3–3.9) | 0.004 | 15/505 | 0.6 (0.3–1.1) | 0.07 | 0.6 (0.3–1.1) | 0.11 |
ARV-related toxicity | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Digestive | 49/506 | 1.6 (0.9–2.8) | 0.05 | 1.5 (0.8–2.6) | 0.15 | 48/505 | 1.8 (1.1–3.0) | 0.03 | 1.7 (0.9–2.9) | 0.05 |
   Dermatologic | 31/506 | 1.8 (1.1–2.9) | 0.03 | 1.6 (0.9–2.8) | 0.08 | 21/505 | 0.9 (0.5–1.6) | 0.82 | - | - |
   General symptoms* | 30/506 | 2.3 (1.4–3.9) | 0.002 | 2.6 (1.5–4.5) | 0.001 | 17/505 | 0.9 (0.5–1.6) | 0.74 | - | - |
Poor adherence to ART (<95% vs. ≥ 95%) | ||||||||||
   % pills taken in last 4d | 11/506 | 1.8 (0.0–3.8) | 0.11 | 1.1 (0.4–2.6) | 0.85 | 17/505 | 4.0 (2.1–7.7) | 0.0001 | 3.8 (1.9–7.4) | <0.0001 |
   30-day VAS | 19/506 | 3.4 (1.8–6.4) | 0.0002 | 3.9 (1.9–7.7) | 0.0001 | - | - | - | - | - |
Nadir CD4 + <50 cells/mm 3 (vs. ≥ 50) | 24/506 | 1.5 (0.9–2.6) | 0.14 | 1.5 (0.8–2.6) | 0.20 | 19/503 | 1.1 (0.6–1.9) | 0.77 | - | - |
Low NNRTI plasma concentration at survey | 17/505 | 1.9 (1.1–3.7) | 0.03 | 2.4 (1.2–4.8) | 0.01 | - | - | - | - | - |